xxxvi
Table 5.1 Role of pharmacogenomics in variable therapy targets .............. 150
Table 5.2 Pharmacogenetic vs. pharmacogenomic studies ......................... 151
Table 5.3 Role of pharmacogenomics in clinical trials ............................... 154
Table 5.4 Examples of pharmacogenomics-based clinical studies ............. 155
Table 10.1 Factors that drive the development of personalized
therapy in cancer ......................................................................... 200
Table 10.2 Impact of molecular diagnostics
on the management of cancer ...................................................... 202
Table 10.3 Marketed anticancer personalized medicines ............................. 237
Table 10.4 Clinical trials of personalized cancer vaccines ........................... 252
Table 12.1 Applications of genomics in neurology ...................................... 411
Table 12.2 Disease-specifi c proteins in CSF of patients
with neurologic disorders ............................................................ 415
Table 12.3 Neurodegenerative diseases with underlying
protein abnormalities................................................................... 416
Table 12.4 Biomarkers of epilepsy ............................................................... 426
Table 12.5 Infl uence of gene polymorphisms on effi cacy
of antiepileptic drugs ................................................................... 430
Table 12.6 Role of cell therapy in management of stroke
according to stage ........................................................................ 439
Table 12.7 Gene expression as biomarker of response
to IFN-β in multiple sclerosis ...................................................... 446
Table 12.8 P450 isoforms in the metabolism of drugs used
in the management of pain .......................................................... 449
Table 12.9 Personalized management of neuropathic pain
based on mechanism ................................................................... 453
Table 13.1 Enzymes that metabolize antipsychotics ..................................... 466
Table 13.2 Enzymes that metabolize antidepressants ................................... 468
Table 13.3 Biomarkers of response to antidepressant treatment ................... 469
Table 13.4 Genetic infl uences on pharmacotherapy of alcoholism .............. 475
Table 14.1 Gene polymorphisms relevant to cardiovascular
disease management .................................................................... 481
Table 14.2 Genes that cause cardiovascular diseases ................................... 483
Table 15.1 Biomarkers of pulmonary diseases ............................................. 512
Table 16.1 Mutation detection technologies ................................................. 534
Table 16.2 Gene therapy approaches to Duchenne muscular dystrophy ...... 545
Table 20.1 Players in the development of personalized medicine ................ 590
Table 20.2 Members of the personalized medicine coalition ....................... 591
Table 20.3 Role of bioinformatics in the development
of personalized medicine ............................................................ 635
List of Tables